ClinicalTrials.gg
CompletedNCT05034822Updated Sep 15, 2023

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

A Phase 1 interventional study of Ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 15 sites in United States. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
14th of 15
29 · median 77
Started
2021
with 3 others
Phase 1
3 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 14th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Read the detailed description

Open-label, BID application to all affected areas identified at BSLN for 4 weeks (maximum use trial (MUsT) period). The next 4 weeks (treatment extension period) will be applied BID to active lesions only for the next 4 weeks for a total treatment period of 8 weeks. Eligible participants will be offered option to continue into 44-wk LTS period of BID to treat as-needed to active lesions. All participants will have 30 day safety follow-up visit.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • pediatric
  • Atopic dermatitis
  • ruxolitinib cream
  • maximum use
  • open label
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female children aged ≥ 2 years to \< 12 years (age at the screening visit).
  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria.
  • AD duration of at least 3 months (participant/parent/guardian may verbally report signs and symptoms of AD with onset at least 3 months prior to screening).
  • An IGA score as follows:

    • Treatment period: ≥ 2 at the screening and baseline visits.
    • LTS period: 0 to 4 at Week 8
  • %BSA (excluding the scalp) with AD involvement as follows:

    • Treatment period: ≥ 35% at screening and baseline
    • LTS period: 0% to 20% at Week 8
  • For children aged 6 years to \< 12 years, mean Itch NRS score ≥ 4 during the screening period.
  • Participants/guardians who agree to discontinue all agents used by the participant to treat AD from the screening visit through the final safety follow-up visit.
  • At least 1 target lesion that measures approximately 5 cm2 or more at the screening and baseline visits. The target lesion must be representative of the participant's disease state but not located on the face, hands, feet, or genitalia.
  • For sexually active participants, willingness to take appropriate measures to avoid pregnancy or fathering a child for the duration of study participation with the exception of male and female participants who are prepubescent.
  • Ability to comprehend and willingness to sign an ICF or written of the parent(s) or legal guardian and a verbal or written assent from the participant when possible.

Exclusion criteria

Exclusion Criteria:

  • An unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator over the previous 4 weeks prior to the baseline visit.
  • Concurrent conditions and history of other diseases as follows:

    • (eg, lymphoma, acquired immunodeficiency syndrome,
    • Wiskott-Aldrich syndrome) or a history of malignant disease within 5 years before the baseline visit.
    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit.
    • Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chickenpox, clinically infected AD, impetigo) within 1 week before the baseline visit.
    • Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton syndrome), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of AD lesions or compromise participant safety.
    • Other types of eczema.
    • Chronic asthma requiring more than 800 μg/day of inhaled budesonide or equivalent high dose of other inhaled .
    • A medical history of virus or virus infection.
    • Any participant on maintenance dialysis.
  • Any of the following clinical laboratory test results at screening:

    • Cytopenias at screening, defined as follows:
    • \< 10 g/dL
    • ANC \< 1000/µL
    • count \< 100,000/µL
    • Liver function tests:
    • or ALT ≥ 2.5 ×
    • Total > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%).
    • Estimated \< 30 mL/min/1.73 m2 (using the Modification of Diet in Renal Disease equation)
    • Positive serology test results at screening for antibody.
    • Any other laboratory result that, in the opinion of the investigator, pose a significant risk to the participant
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Use of any of the following treatments within the indicated before the baseline visit:

    • 5 half-lives or 12 weeks, whichever is longer - biologic agents (eg, dupilumab).
    • 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogues, cyclosporine, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (eg, mycophenolate, choroquine or tacrolimus).
    • 2 weeks - immunizations with ; sedating antihistamines unless on a long-term stable regimen (nonsedating antihistamines are permitted). Note: Live-attenuated vaccines are not recommended during the treatment period of the study. COVID-19 vaccines are allowed during the study.
    • 1 week - use of topical treatments for AD (other than bland emollients, creams, ointments, sprays, soap substitutes), topical antipruritics (eg, doxepin cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), topical antibiotics, or antibacterial cleansing body wash/soap. Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week.
  • Previous treatment with systemic or topical JAK inhibitors (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
  • Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the participant's AD.
  • Known or suspected to either ruxolitinib or any component of its cream vehicle.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the baseline visit with another medication or current enrollment in another investigational drug protocol.
  • Inadequate venous access in nonlesional areas for laboratory blood draws.
  • In the opinion of the investigator, unable or unlikely to comply with the administration schedule and study evaluations.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Ruxolitinib cream

    ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD

    Drug: Ruxolitinib cream

Interventions

  • Ruxolitinib 1.5% cream applied twice daily.

    Also known as: INCB018424 phosphate cream

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events

    Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first application of study drug

    Time frame: Up to approximately 61 weeks

Secondary outcomes

  1. Concentration of Ruxolitinib in plasma

    Time frame: Day 1, Weeks 2, 4 and 8

  2. Plasma Css of Ruxolitinib

    Time to reach steady state concentration plateau of topical application under maximum use conditions

    Time frame: Weeks 2 and 4

  3. Accumulation ratio of Ruxilitinib

    Accumulation ratio of ruxolitinib between plasma concentrations at 1 hour post application will be calculated and summarized in the age group of 7 to 11 years

    Time frame: Day 1, Weeks 2, 4 and 8

07

Study locations

15 sites
  • Desert Sky Dermatology
    Gilbert, Arizona 85295, United States
  • Burke Pharmaceutical Research
    Hot Springs National Park, Arkansas 71913, United States
  • Orange County Research Center
    Anaheim, California 92801, United States
  • Skin Care Research, Llc Scr Hollywood
    Hollywood, Florida 33021, United States
  • Accel Clinical Research
    Lake Mary, Florida 32746, United States
  • San Marcus Research Clinic Inc.
    Miami Lakes, Florida 33014, United States
  • Forward Clinical Trials
    Tampa, Florida 33624, United States
  • Advanced Medical Research Pc
    Sandy Springs, Georgia 30328, United States
  • Aeroallergy Research Lab of Savannah
    Savannah, Georgia 31406, United States
  • Oakland Hills Dermatology Pc
    Auburn Hills, Michigan 48326, United States
  • Skin Cancer and Dermatology Institute
    Reno, Nevada 89509, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Cyn3Rgy Research - Clinedge - Ppds
    Gresham, Oregon 97030, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2023, 19 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 19 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 5, 2021
StartActual
Dec 16, 2021
Primary completionActual
Aug 7, 2023
CompletionActual
Aug 7, 2023
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05034822
Lead sponsor
Incyte Corporation
Collaborators
Innovaderm Research
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Dec 16, 2021
Primary completion
Aug 7, 2023
Completion
Aug 7, 2023
Last update
Sep 15, 2023

Study contacts

Haq Nawaz, MD, MPH, MBA, MS
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion